Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

News SummaryMost relevantAll newsSector newsTweets 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
04/29 NOVARTIS : Korea fined W55b, faces insurance coverage ban over bribery
04/28 NOVARTIS : expands global collaboration with Amgen to commercialize first-in-cla..
04/28 NOVARTIS : receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acu..
04/28 NOVARTIS : to globally co-commercialise Amgens migraine drug
04/28 NOVARTIS : FDA approves 1st targeted drug for certain leukemia patients
04/27 NOVARTIS : Patent Issued for Formulation Comprising Benzothiazolone Compound (US..
04/27 NOVARTIS : Allergan Expands Leading Research & Development NASH Program with Nov..
04/27 NOVARTIS : Patent Issued for Process for Manufacturing an Ophthalmic Lens (USPTO..
04/27 NOVARTIS : Patent Issued for Process for Preparing Intermediates Useful in the M..
04/27 NOVARTIS : NIH study in NEJM shows Novartis drug eltrombopag as first-line thera..
More news
Sector news : Pharmaceuticals - NEC
04/30DJPFIZER : Drug Makers Take Page From Hollywood to Spread the Risk
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 FDA OKs Novartis' leukemia med Rydapt
04/27 BRISTOL-MYERS SQUIBB : Becoming An Increasingly Attractive Target
04/27 Amgen's Q1 Shows Challenges And Growth Opportunities Aplenty
04/27 G1 Therapeutics Seeks $115 Million IPO
Financials ($)
Sales 2017 48 401 M
EBIT 2017 12 327 M
Net income 2017 7 451 M
Debt 2017 14 141 M
Yield 2017 3,68%
P/E ratio 2017 22,76
P/E ratio 2018 20,05
EV / Sales 2017 4,47x
EV / Sales 2018 4,28x
Capitalization 202 360 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 31
Average target price 79,7 $
Spread / Average Target 3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG3.31%202 360
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
SANOFI12.63%121 897
More Results